Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease

April D. Lake, Petr Novak, Petia Shipkova, Nelly Aranibar, Donald Robertson, Michael D. Reily, Zhenqiang Lu, Lois D. Lehman-McKeeman, Nathan J Cherrington

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Bile acids (BAs) have many physiological roles and exhibit both toxic and protective influences within the liver. Alterations in the BA profile may be the result of disease induced liver injury. Nonalcoholic fatty liver disease (NAFLD) is a prevalent form of chronic liver disease characterized by the pathophysiological progression from simple steatosis to nonalcoholic steatohepatitis (NASH). The hypothesis of this study is that the 'classical' (neutral) and 'alternative' (acidic) BA synthesis pathways are altered together with hepatic BA composition during progression of human NAFLD. This study employed the use of transcriptomic and metabolomic assays to study the hepatic toxicologic BA profile in progressive human NAFLD. Individual human liver samples diagnosed as normal, steatosis, and NASH were utilized in the assays. The transcriptomic analysis of 70 BA genes revealed an enrichment of downregulated BA metabolism and transcription factor/receptor genes in livers diagnosed as NASH. Increased mRNA expression of BAAT and CYP7B1 was observed in contrast to decreased CYP8B1 expression in NASH samples. The BA metabolomic profile of NASH livers exhibited an increase in taurine together with elevated levels of conjugated BA species, taurocholic acid (TCA) and taurodeoxycholic acid (TDCA). Conversely, cholic acid (CA) and glycodeoxycholic acid (GDCA) were decreased in NASH liver. These findings reveal a potential shift toward the alternative pathway of BA synthesis during NASH, mediated by increased mRNA and protein expression of CYP7B1. Overall, the transcriptomic changes of BA synthesis pathway enzymes together with altered hepatic BA composition signify an attempt by the liver to reduce hepatotoxicity during disease progression to NASH.

Original languageEnglish (US)
Pages (from-to)132-140
Number of pages9
JournalToxicology and Applied Pharmacology
Volume268
Issue number2
DOIs
StatePublished - Apr 5 2013

Fingerprint

Bile Acids and Salts
Liver
Chemical analysis
Metabolomics
Steroid 12-alpha-Hydroxylase
Non-alcoholic Fatty Liver Disease
Liver Diseases
Assays
Glycodeoxycholic Acid
Genes
Taurodeoxycholic Acid
Cholic Acid
Taurocholic Acid
Messenger RNA
Poisons
Taurine
Metabolism
Disease Progression
Chronic Disease
Transcription Factors

Keywords

  • Bile acids
  • Liver
  • Metabolomics
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Transcriptomics

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. / Lake, April D.; Novak, Petr; Shipkova, Petia; Aranibar, Nelly; Robertson, Donald; Reily, Michael D.; Lu, Zhenqiang; Lehman-McKeeman, Lois D.; Cherrington, Nathan J.

In: Toxicology and Applied Pharmacology, Vol. 268, No. 2, 05.04.2013, p. 132-140.

Research output: Contribution to journalArticle

Lake, April D. ; Novak, Petr ; Shipkova, Petia ; Aranibar, Nelly ; Robertson, Donald ; Reily, Michael D. ; Lu, Zhenqiang ; Lehman-McKeeman, Lois D. ; Cherrington, Nathan J. / Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. In: Toxicology and Applied Pharmacology. 2013 ; Vol. 268, No. 2. pp. 132-140.
@article{87f7a0d4820146b7a21fdeadc777c560,
title = "Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease",
abstract = "Bile acids (BAs) have many physiological roles and exhibit both toxic and protective influences within the liver. Alterations in the BA profile may be the result of disease induced liver injury. Nonalcoholic fatty liver disease (NAFLD) is a prevalent form of chronic liver disease characterized by the pathophysiological progression from simple steatosis to nonalcoholic steatohepatitis (NASH). The hypothesis of this study is that the 'classical' (neutral) and 'alternative' (acidic) BA synthesis pathways are altered together with hepatic BA composition during progression of human NAFLD. This study employed the use of transcriptomic and metabolomic assays to study the hepatic toxicologic BA profile in progressive human NAFLD. Individual human liver samples diagnosed as normal, steatosis, and NASH were utilized in the assays. The transcriptomic analysis of 70 BA genes revealed an enrichment of downregulated BA metabolism and transcription factor/receptor genes in livers diagnosed as NASH. Increased mRNA expression of BAAT and CYP7B1 was observed in contrast to decreased CYP8B1 expression in NASH samples. The BA metabolomic profile of NASH livers exhibited an increase in taurine together with elevated levels of conjugated BA species, taurocholic acid (TCA) and taurodeoxycholic acid (TDCA). Conversely, cholic acid (CA) and glycodeoxycholic acid (GDCA) were decreased in NASH liver. These findings reveal a potential shift toward the alternative pathway of BA synthesis during NASH, mediated by increased mRNA and protein expression of CYP7B1. Overall, the transcriptomic changes of BA synthesis pathway enzymes together with altered hepatic BA composition signify an attempt by the liver to reduce hepatotoxicity during disease progression to NASH.",
keywords = "Bile acids, Liver, Metabolomics, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Transcriptomics",
author = "Lake, {April D.} and Petr Novak and Petia Shipkova and Nelly Aranibar and Donald Robertson and Reily, {Michael D.} and Zhenqiang Lu and Lehman-McKeeman, {Lois D.} and Cherrington, {Nathan J}",
year = "2013",
month = "4",
day = "5",
doi = "10.1016/j.taap.2013.01.022",
language = "English (US)",
volume = "268",
pages = "132--140",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease

AU - Lake, April D.

AU - Novak, Petr

AU - Shipkova, Petia

AU - Aranibar, Nelly

AU - Robertson, Donald

AU - Reily, Michael D.

AU - Lu, Zhenqiang

AU - Lehman-McKeeman, Lois D.

AU - Cherrington, Nathan J

PY - 2013/4/5

Y1 - 2013/4/5

N2 - Bile acids (BAs) have many physiological roles and exhibit both toxic and protective influences within the liver. Alterations in the BA profile may be the result of disease induced liver injury. Nonalcoholic fatty liver disease (NAFLD) is a prevalent form of chronic liver disease characterized by the pathophysiological progression from simple steatosis to nonalcoholic steatohepatitis (NASH). The hypothesis of this study is that the 'classical' (neutral) and 'alternative' (acidic) BA synthesis pathways are altered together with hepatic BA composition during progression of human NAFLD. This study employed the use of transcriptomic and metabolomic assays to study the hepatic toxicologic BA profile in progressive human NAFLD. Individual human liver samples diagnosed as normal, steatosis, and NASH were utilized in the assays. The transcriptomic analysis of 70 BA genes revealed an enrichment of downregulated BA metabolism and transcription factor/receptor genes in livers diagnosed as NASH. Increased mRNA expression of BAAT and CYP7B1 was observed in contrast to decreased CYP8B1 expression in NASH samples. The BA metabolomic profile of NASH livers exhibited an increase in taurine together with elevated levels of conjugated BA species, taurocholic acid (TCA) and taurodeoxycholic acid (TDCA). Conversely, cholic acid (CA) and glycodeoxycholic acid (GDCA) were decreased in NASH liver. These findings reveal a potential shift toward the alternative pathway of BA synthesis during NASH, mediated by increased mRNA and protein expression of CYP7B1. Overall, the transcriptomic changes of BA synthesis pathway enzymes together with altered hepatic BA composition signify an attempt by the liver to reduce hepatotoxicity during disease progression to NASH.

AB - Bile acids (BAs) have many physiological roles and exhibit both toxic and protective influences within the liver. Alterations in the BA profile may be the result of disease induced liver injury. Nonalcoholic fatty liver disease (NAFLD) is a prevalent form of chronic liver disease characterized by the pathophysiological progression from simple steatosis to nonalcoholic steatohepatitis (NASH). The hypothesis of this study is that the 'classical' (neutral) and 'alternative' (acidic) BA synthesis pathways are altered together with hepatic BA composition during progression of human NAFLD. This study employed the use of transcriptomic and metabolomic assays to study the hepatic toxicologic BA profile in progressive human NAFLD. Individual human liver samples diagnosed as normal, steatosis, and NASH were utilized in the assays. The transcriptomic analysis of 70 BA genes revealed an enrichment of downregulated BA metabolism and transcription factor/receptor genes in livers diagnosed as NASH. Increased mRNA expression of BAAT and CYP7B1 was observed in contrast to decreased CYP8B1 expression in NASH samples. The BA metabolomic profile of NASH livers exhibited an increase in taurine together with elevated levels of conjugated BA species, taurocholic acid (TCA) and taurodeoxycholic acid (TDCA). Conversely, cholic acid (CA) and glycodeoxycholic acid (GDCA) were decreased in NASH liver. These findings reveal a potential shift toward the alternative pathway of BA synthesis during NASH, mediated by increased mRNA and protein expression of CYP7B1. Overall, the transcriptomic changes of BA synthesis pathway enzymes together with altered hepatic BA composition signify an attempt by the liver to reduce hepatotoxicity during disease progression to NASH.

KW - Bile acids

KW - Liver

KW - Metabolomics

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=84875066303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875066303&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2013.01.022

DO - 10.1016/j.taap.2013.01.022

M3 - Article

C2 - 23391614

AN - SCOPUS:84875066303

VL - 268

SP - 132

EP - 140

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -